This is a weekly column about the five biggest funding rounds of the past week.

Weekly Review

Link copied

12:20 | 27 February 2023

This is a weekly column about the five biggest funding rounds of the past week.

This past week has not been rich in major funding rounds. Only two companies received more than $100 million.

Spreetail, $208M.

Sector: retail.
Spreetail serves more than 500 brands, helping them drive their e-commerce sales – with analytics, insight and logistics – to major platforms like Amazon, Walmart.com and other sites.Spreetail closed a $208 million funding round last week, with McCarthy Capital, internal management and other investors as the main investors.

Vytalize Health, $100M.

Sector: healthcare.
Value-based services company Vytalize Health closed a $100 million funding round last week with Enhanced Healthcare Partners and Monroe Capital as major investors. The company will use the investment to further develop its virtual and home-based primary care offerings for seniors. Vytalize Health works with primary care providers with more than 250,000 patients to help with data-driven care recommendations. The company is trying to fill gaps in needed and regular doctor visits for seniors to avoid unnecessary trips to the emergency room. The startup has raised about $176 million in total.

ProsperOps, $72M.

Sector: cost optimization.
Most companies use cloud storage, but unfortunately the price of this service is rising. The startup ProsperOps offers a platform to optimize the cost of cloud services so customers can track usage, save and maximize their costs.
The company received a $72 million investment last week, with H.I.G. Growth Partners and other strategic investors as the main investors.

Tome, $43M.

Sector: artificial intelligence.
A lot of companies in the AI sector are attracting investments for their development these days, and Tome is no exception. The San Francisco-based startup uses artificial intelligence to help turn users’ ideas into a more compelling visual narrative. In a way, it’s kind of like a powerpoint presentation. The company raised a $43 million Series B, with Lightspeed Venture Partners as the main investors. Cumulatively, the company has raised $81 million since it was founded.

Transcend Therapeutics, $40M.

Sector: biotechnology.
More than 50 million Americans suffer from neuropsychiatric disorders, including post-traumatic stress disorder. New York-based company Transcend Therapeutics aims to help some of these unfortunates. The company closed a $40 million Series A, with Alpha Wave Global and Integrated Investment Partners as major investors. The company plans to use the cash infusion to launch several clinical trials, including a Phase II study, with its next-generation psychoactive compound. Transcend was founded in 2021 and has raised about $42 million to date.

We’ve summarized last week’s results and hope you found the information useful.Stay tuned for more information.

Uncategorized

19:11 | Apr 05, 2024

Toncoin enters top 10 crypto by market capitalization, overtakes Avalanche

Toncoin, The Open Network’s native cryptocurrency token, has once again entered the list of the 10 most significant coins by […]

Uncategorized

16:21 | Mar 04, 2024

Bitcoin Tops $65K as Bullish Bets Climb to Record High

The largest cryptocurrency is now just 5% away from its 2021 high in U.S. dollar terms, having already reached records […]

Hereby "Global Venture Partners s.r.o." notifies that it carries out its activities in accordance with paragraph 1 of article 15, the law on investment companies and investment funds of 19.06.2019. Listed in the ZISIF § 15 para. 1 asset management list managed by the CNB in accordance with § 596 (1) CRR. (F) ZISIF.

IČO: 08241473. LEI: 5493003MKEWYLZ837883...
This information on the site is not an individual investment recommendation, and the financial instruments or transactions mentioned in this material may not correspond to your investment profile, financial situation, investment experience, investment goals. Determining the compliance of a financial instrument or transaction with investment objectives, investment horizon and risk tolerance is the task of the investor
Venture fund Global Venture Partners s.r.o. is not responsible for possible losses of the investor in case of investing in the financial instruments mentioned in this material and does not recommend using the specified information as the only source of information when making an investment decision.
* The Venture Fund does not provide guarantees regarding the reliability and accuracy of the information provided, none of the assumptions contained in this material can be interpreted as a guarantee of investment reliability, income stability and possible benefits associated with management methods or the choice of specific financial instruments. The value of investment products may increase and decrease, the results of investing in the past do not determine future income, the company does not guarantee the profitability of investments in investment funds. All information about the profitability (value gain) of the product managed by Global Venture Partners s.r.o. are quoted excluding commissions and taxes. Charging a commission will reduce the return on investment in investment products. Before purchasing an investment product, you should carefully read the rules of trust management for this product. Services for transactions with foreign securities are available to persons who are qualified investors in accordance with applicable law and are performed in accordance with the restrictions established by applicable law.

Show

Hide